OBJECTIVE: High-density lipoprotein (HDL) levels are inversely proportional to the risk of atherosclerosis, but mechanisms of HDL atheroprotection remain unclear. Monocyte chemoatractant protein-1 (MCP-1) constitutes an early component of inflammatory response in atherosclerosis. Here we investigated the influence of HDL on MCP-1 production in vascular smooth muscle cells (VSMCs) and rat aortic explants. METHODS AND RESULTS: HDL inhibited the thrombin-induced production of MCP-1 in a concentration-dependent manner. The HDL-dependent inhibition of MCP-1 production was accompanied by the suppression of reactive oxygen species (ROS), which regulate the MCP-1 production in VSMCs. HDL inhibited NAD(P)H oxidase, the preponderant source of ROS in the vasculature, and prevented the activation of Rac1, which precedes NAD(P)H-oxidase activation. The HDL capacity to inhibit MCP-1 production, ROS generation, and NAD(P)H-oxidase activation was emulated by sphingosine 1-phosphate (S1P) and sphingosylphosphorylcholine (SPC), two lysosphingolipids present in HDL, but not by apolipoprotein A-I. HDL-, S1P-, and SPC-induced inhibition of MCP-1 production was attenuated in VSMCs pretreated with VPC23019, an antagonist of lysosphingolipid receptors S1P(1) and S1P(3), but not by JTE013, an antagonist of S1P(2). In addition, HDL, S1P, and SPC failed to inhibit MCP1 production and ROS generation in aortas from S1P(3)- and SR-B1-deficient mice. CONCLUSIONS: HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent ROS generation and MCP-1 production in a process that requires coordinate signaling through S1P(3) and SR-B1 receptors.
OBJECTIVE: High-density lipoprotein (HDL) levels are inversely proportional to the risk of atherosclerosis, but mechanisms of HDL atheroprotection remain unclear. Monocyte chemoatractant protein-1 (MCP-1) constitutes an early component of inflammatory response in atherosclerosis. Here we investigated the influence of HDL on MCP-1 production in vascular smooth muscle cells (VSMCs) and rat aortic explants. METHODS AND RESULTS: HDL inhibited the thrombin-induced production of MCP-1 in a concentration-dependent manner. The HDL-dependent inhibition of MCP-1 production was accompanied by the suppression of reactive oxygen species (ROS), which regulate the MCP-1 production in VSMCs. HDL inhibited NAD(P)H oxidase, the preponderant source of ROS in the vasculature, and prevented the activation of Rac1, which precedes NAD(P)H-oxidase activation. The HDL capacity to inhibit MCP-1 production, ROS generation, and NAD(P)H-oxidase activation was emulated by sphingosine 1-phosphate (S1P) and sphingosylphosphorylcholine (SPC), two lysosphingolipids present in HDL, but not by apolipoprotein A-I. HDL-, S1P-, and SPC-induced inhibition of MCP-1 production was attenuated in VSMCs pretreated with VPC23019, an antagonist of lysosphingolipid receptors S1P(1) and S1P(3), but not by JTE013, an antagonist of S1P(2). In addition, HDL, S1P, and SPC failed to inhibit MCP1 production and ROS generation in aortas from S1P(3)- and SR-B1-deficient mice. CONCLUSIONS: HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent ROS generation and MCP-1 production in a process that requires coordinate signaling through S1P(3) and SR-B1 receptors.
Authors: Philip J Barter; Stephen Nicholls; Kerry-Anne Rye; G M Anantharamaiah; Mohamad Navab; Alan M Fogelman Journal: Circ Res Date: 2004-10-15 Impact factor: 17.367
Authors: G W De Keulenaer; M Ushio-Fukai; Q Yin; A B Chung; P R Lyons; N Ishizaka; K Rengarajan; W R Taylor; R W Alexander; K K Griendling Journal: Arterioscler Thromb Vasc Biol Date: 2000-02 Impact factor: 8.311
Authors: Petra Keul; Markus Tölle; Susann Lucke; Karin von Wnuck Lipinski; Gerd Heusch; Mirjam Schuchardt; Markus van der Giet; Bodo Levkau Journal: Arterioscler Thromb Vasc Biol Date: 2006-12-07 Impact factor: 8.311
Authors: Mirjam Schuchardt; Jasmin Prüfer; Nicole Prüfer; Annette Wiedon; Tao Huang; Miriam Chebli; Vera Jankowski; Joachim Jankowski; Monika Schäfer-Korting; Walter Zidek; Markus van der Giet; Markus Tölle Journal: J Mol Med (Berl) Date: 2011-04-13 Impact factor: 4.599
Authors: A Tran-Dinh; D Diallo; S Delbosc; L Maria Varela-Perez; Q B Dang; B Lapergue; E Burillo; J B Michel; A Levoye; J L Martin-Ventura; O Meilhac Journal: Br J Pharmacol Date: 2013-06 Impact factor: 8.739